Skip to content

CYPH CYPH Stock-Based Comp

Stock-Based Comp at other companies

Pfizer logo
PfizerPFE
$272M+60.0%
Merck & Co. logo
Merck & Co.MRK
$185M-5.1%
Amgen logo
AmgenAMGN
$75M-11.8%
MicroStrategy logo
MicroStrategyMSTR
$13.17M+11.5%
Ziff Davis logo
Ziff DavisZD
$10.91M+11.9%
Zscaler logo
ZscalerZS
$205.19M+28.7%

Other financials

Income statement

See full
Revenue$375.0K
Operating income-$4.8M+69.7%
Net income-$77.2M-400%
EPS (diluted)-$0.46-24.3%

Balance sheet

See full
Cash & equivalents$6.7M-79.6%
Total debt$38.0K-75.3%
Total equity$84.4M+305%
Total assets$87.4M+151%

Cash flow

See full
Operating cash flow-$3.4M+76.3%

Valuation

See full
Market cap$65.19M-58.2%
Enterprise value$58.54M
P/S43.5×

Profitability

See full
Operating margin-2,761.7%
Net margin-2,705.8%

Returns & leverage

See full
Return on equity-108.2%-34.4pp
Debt / equity0.0×
Current ratio27.3×+24.9×

Where this comes from

Reported directly by CYPH in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: CYPH’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CYPH's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CYPH's stock-based comp?
CYPH (CYPH) reported stock-based comp of $2.13M in Q1 2026.
How has CYPH's stock-based comp changed year-over-year?
CYPH's stock-based comp increased by 77.0% year-over-year, from $1.2M to $2.13M.
What is the long-term trend for CYPH's stock-based comp?
Over 3 years (2021 to 2025), CYPH's stock-based comp has grown at a 9.9% compound annual growth rate (CAGR), from $3.69M to $4.9M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.